SecBot SecBot
6-K ·Filed Apr 17, 2026

EVAX

Evaxion A/S
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago SEC0001171843-26-002532
Notable filing: 6-K
Actionable Insight ▲ Bullish

The 86% target precision rate is a strong technical validation of Evaxion's AI platform, which could enhance confidence in its broader pipeline. Traders should monitor the upcoming AACR presentation and anticipate potential partnership interest or follow-on clinical developments. The robust immune response data may reprice expectations for EVX-01's clinical efficacy, especially given the 75% ORR already observed.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.45
T+0 close · Apr 17, 2026 · via day close
Latest settled
−31.91%
T+60 · $3.03
Vs SPY
−38.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $4.45entry
  2. T+1 · 7mo ago +0.90%α +1.09% · $4.49
  3. T+5 · 7mo ago −9.44%α −9.99% · $4.03
  4. T+20 · 6mo ago −7.42%α −12.79% · $4.12
  5. T+60 · 4mo ago −31.91%α −38.05% · $3.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion A/S announced phase 2 trial data showing its AI-designed personalized cancer vaccine EVX-01 achieved an 86% success rate in triggering tumor-specific immune responses, a key validation of its AI-Immunology platform. The results, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the vaccine's therapeutic potential in advanced melanoma.

Key Facts

  • 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, described as a record high
  • Durable vaccine-specific immune responses observed over two years
  • High de novo T-cell response rate (86%) indicates strong immune system activation
  • Positive correlation between AI-prediction scores and immune response magnitude confirmed
  • Trial conducted in advanced melanoma patients using EVX-01 in combination with KEYTRUDA (pembrolizumab)
  • Two-year clinical data previously showed a 75% Objective Response Rate
  • Three-year clinical data expected in H2 2026

Financial Impact

High potential long-term value given platform validation and lead asset advancement; no immediate financials reported

pipeline valueplatform credibilitydevelopment risk

Risk Factors

  • Clinical trial results do not guarantee regulatory approval
  • Small market cap ($35M) increases volatility risk
  • Dependence on future clinical data and external funding

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-002532
Document: f6k_041726.htm0001171843-26-002532
Document: 0001171843-26-002532-index-headers.html0001171843-26-002532
Document: 0001171843-26-002532-index.html0001171843-26-002532
Document: 0001171843-26-002532.txt0001171843-26-002532

Track record

50 reports on EVAX

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026